Enanta Pharmaceuticals, Inc.
330 articles about Enanta Pharmaceuticals, Inc.
-
Enanta Pharmaceuticals, Inc. Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference
9/30/2016
-
Enanta Pharmaceuticals, Inc. Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-Alcoholic Steatohepatitis (NASH)
9/29/2016
-
Enanta Pharmaceuticals, Inc. Announces Data On Eight-Week Treatment Of AbbVie’s VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C
9/23/2016
-
Enanta Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences
8/29/2016
-
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2016
8/9/2016
-
Enanta Pharmaceuticals, Inc. Announces The U.S.FDA Has Approved AbbVie’s New, Once-Daily VIEKIRA XR (Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus
7/26/2016
-
Enanta Pharmaceuticals, Inc. To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016
7/18/2016
-
Enanta Pharmaceuticals, Inc. Initiates Proof-Of-Concept Study With Pan-Genotypic Cyclophilin Inhibitor EDP-494 In Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C Virus
6/20/2016
-
Enanta Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences
6/2/2016
-
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016
5/10/2016
-
Enanta Pharmaceuticals, Inc. To Host Conference Call On May 9 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2016
4/28/2016
-
Enanta Pharmaceuticals, Inc. To Present At The Deutsche Bank 41st Annual Healthcare Conference Presentation To Be Webcast On May 4, 2016 At 8:00 A.M. ET
4/26/2016
-
Enanta Pharmaceuticals, Inc. Announces FDA Has Approved AbbVie’s Supplemental New Drug Application For Use Of VIEKIRA PAK Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis
4/25/2016
-
Enanta Pharmaceuticals, Inc. Announces New Data From AbbVie’s SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus
4/18/2016
-
Enanta Pharmaceuticals, Inc. Announces That AbbVie’s Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals
4/15/2016
-
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie’s VIEKIRAX + EXVIERA Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients
4/15/2016
-
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie’s Viekirax + Exviera Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients
4/14/2016
-
Enanta Pharmaceuticals, Inc. Announces HCV Data Presentations At The International Liver Congress 2016
3/30/2016
-
Enanta Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference
3/10/2016
-
Enanta Pharmaceuticals, Inc. Announces CHMP Positive Opinion For AbbVie’s VIEKIRAX + EXVIERA® Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis
2/26/2016